Articles tagged with Chemotherapy
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
A new study published in JAMA Oncology found that chemotherapy before surgery can improve survival rates for patients with pancreatic ductal adenocarcinoma (PDAC), an aggressive form of the disease. The modified FOLFIRINOX regimen was administered to 46 patients, resulting in a 67% 12-month progression-free survival rate and a 59% two-...
Researchers at Linköping University and the Medical University of Graz have developed a new cancer treatment using an iontronic pump to deliver continuous, low-dose chemotherapy directly to brain tumors. This approach significantly reduces tumor growth by bypassing the blood-brain barrier, a common obstacle to effective treatment.
The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
Researchers at Virginia Tech have discovered a possible new pathway to treat colorectal cancer by targeting the NF-kB-inducing kinase (NIK) protein. The study, led by Irving Coy Allen, identifies changes in a significant signaling pathway in human patients and presents potential targets for therapeutics.
Researchers developed microscopic robots that swim through lungs to deliver cancer-fighting medication directly to metastatic tumors. The approach inhibited tumor growth and spread, improving survival rates compared to control treatments.
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
Researchers developed a novel immunotherapy approach using ultrasound to deliver chemotherapy and antibodies to the brain, boosting immune system recognition of glioblastoma cells. The treatment showed promise in improving responses to PD-1 blockade in patients with advanced brain tumors.
Researchers created nanomicelles containing substances already approved for human use, which reduced inflammation in the tumor microenvironment and facilitated the action of the immune system. The treatment induced a reduction of over five times in tumor volume compared to untreated tumors.
Researchers developed a prodrug delivery method using a commensal Lactobacillus strain that binds specifically to cancer cells, releasing the chemotherapy drug SN-38 directly at the tumour site. This approach reduces tumour growth by 67% and increases chemotherapy drug effectiveness by 54% in preclinical models of nasopharyngeal cancer.
The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.
A new study by ECOG-ACRIN Cancer Research Group aimed to address disparities in breast cancer care for Black patients. The trial found that tailoring research to the needs of underserved groups is effective, with docetaxel showing lower rates of peripheral neuropathy and dose reductions compared to paclitaxel.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
Ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared to chemotherapy alone in TKI-treated non-small cell lung cancer patients. This treatment may offer a new option for patients with EGFR variant and limited treatment options.
Researchers at King's College London have developed a novel drug delivery system using biologically compatible peptides found in chicken feathers and skin tissue. This innovative approach enables targeted delivery of chemotherapy drugs and repair of faulty enzymes, potentially reducing side effects and improving treatment outcomes.
Researchers found that five cannabis terpenes reduced chronic neuropathic pain levels comparable to morphine. The combination of terpenes and morphine enhanced pain relief without negative side effects. Terpenes offer an alternative to opioids for pain management with a better side effect profile.
Researchers at MUSC Hollings Cancer Center discover polyploid giant cancer cells can lead to disease recurrence after chemotherapy or radiotherapy. They found that targeting these 'monster cells' could prevent tumor relapse, and potential therapies like tamoxifen and statins may also be effective.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
SWOG Cancer Research Network will share results of their work in 30 presentations at the 2024 American Society of Clinical Oncology Annual Meeting, May 31 – June 4 in Chicago. The research focuses on improving cancer treatments and reducing devastating side effects.
A Phase III randomized, placebo-controlled trial found that donepezil did not improve memory or other cognitive functions in breast cancer survivors. Despite this, researchers emphasize the need for further trials with different approaches to address cancer-related cognitive impairment.
Researchers found that blocking PI3K-beta makes glioblastoma cells more sensitive to temozolomide treatment, slowing down tumor growth. The study's findings could lead to new treatments for patients with chemotherapy-resistant glioblastoma.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
Researchers found a new pathway to cancer cell death led by the Schlafen11 (SLFN11) gene. This discovery could have implications for cancer treatment and patient outcomes.
A UCLA-led study reveals that chemotherapy for early-stage breast cancer in women over 65 can lead to a significant decline in physical function. The study found that 30% of older women who received chemotherapy experienced a substantial decline, with climbing stairs and walking being the most affected activities.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Researchers found that SARS-CoV-2 spike protein interrupts p53-MDM2 interaction but does not bind with p53 protein in cancer cells. The study also shows that SARS-CoV-2 spike suppresses p53-dependent gene activation, leading to increased cell viability after chemotherapy exposure.
MIT engineers have developed a closed-loop drug-delivery system that can improve chemotherapy outcomes by continuously monitoring patients and adjusting dosage. The new system, called CLAUDIA, uses commercially available equipment to analyze blood samples every five minutes and adjust infusion rates in real-time.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
A new study published in JNCI Cancer Spectrum found that following a healthy diet, such as the DASH diet, lowers the risk of cardiovascular disease in breast cancer survivors. Women whose diets were most similar to DASH had a 47% lower risk of heart failure and other cardiovascular-related events.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.
Researchers developed a nanosized polymer that selectively delivers chemotherapeutic drugs to blood vessels supporting tumor growth. The treatment eliminates colorectal cancer liver metastases and prolongs mice survival after a single dose-therapy.
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
Researchers from the University of Southern Denmark have identified specific groups of cells driving resistance to chemotherapy in TNBC, offering new biomarkers and alternative treatment options. The studies shed light on the mechanisms behind chemoresistance and its epigenetic control.
Researchers developed an AI model to detect viable tumor cells in osteosarcoma patients, improving prognosis predictions. The model showed comparable detection performance to pathologists and reduced inter-assessor variability, enabling timely assessment.
A new study suggests that early-stage triple-negative breast cancer (TNBC) patients with high levels of immune cells in their tumors may have a lower risk of recurrence and better survival rates even without chemotherapy. Higher TILs in breast cancer tissue were associated with lower recurrence rates among participants.
A nationwide study finds that individuals diagnosed with colon cancer who resided in previously redlined neighborhoods are more likely to be diagnosed with advanced-stage disease and have worse survival rates. The research highlights the long-lasting impact of institutional racism on access to quality cancer care.
The study found that neoadjuvant chemotherapy increased median overall survival to 37 months and progression-free survival to 26 months. 57.2% of patients showed an objective response, with nearly one-fourth experiencing lymph-node pathologic complete response.
Researchers have identified a protein, NPEPPS, that enables cisplatin-resistant cancer cells to become responsive to treatment. This discovery could increase patient eligibility and make platinum-based therapies more effective.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
The University of Cincinnati Cancer Center team has opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, a deadly form of brain tumors. The treatment uses letrozole, a drug that targets an enzyme present in breast cancer cells, and temozolomide, a chemotherapy drug already approved as a GBM treatment.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
A team of scientists discovered new fusion sites in protein evolution that enable faster and more targeted drug development. By combining evolutionary processes with synthetic biology, they created customized biological drugs with improved therapeutic properties.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
A study by IRB Barcelona and Sant Joan de Déu Hospital reveals three distinct patterns explaining the occurrence of second cancers in children, including a mutational footprint from chemotherapy. The research advances understanding of pediatric cancer and highlights the importance of clinical data sharing.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Researchers at MIT discovered that daily exposure to light and sound with a frequency of 40 hertz protects brain cells from chemotherapy-induced damage, preventing memory loss and improving cognitive functions. The treatment also helped prevent DNA damage, inflammation, and promoted the growth of oligodendrocytes, the cells responsible...
A new study reveals that MAGE family proteins bind to RAD18 using a groove, preventing its degradation and contributing to cancer progression. The findings also suggest that blocking this interaction could lead to re-sensitization of cancer cells to chemotherapy and radiotherapy.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
Researchers developed an oxidative stress-based prognostic model for bladder cancer, identifying distinct molecular subtypes and predicting patient outcomes. The model shows promise in tailoring personalized treatment approaches, particularly for patients with low-risk profiles.
Head and neck cancer patients exposed to secondhand smoke during chemotherapy have reduced treatment effectiveness. Secondhand smoke alters protein expression, restricting chemotherapy's ability to kill cancer cells. This raises concerns about cancer prognosis and the importance of smoking cessation.
Two new studies reveal that UK cancer patients face long waits for chemotherapy and radiotherapy, leading to poorer outcomes. The research highlights the need for a strategic approach to addressing treatment variation and improving cancer services in the UK.